Altimmune, Inc. (NASDAQ:ALT) earns a spot on our list of the top 10 stocks under $5 that could triple. H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases On March 16, 2026, H.C. Wainwright noted growing optimism around pipeline expansion and upside potential by raising the price target for Altimmune, Inc. (NASDAQ:ALT) from $12 to $25, while maintaining a “Buy” rating on the stock. Altimmune, Inc. (NASDAQ:ALT)’s strategic focus on its MASH program ...